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Abstract: 10 
 Infertility is a growing issue in modern society, being the fifth highest serious 11 
global disability according to the World Health Organization. To study infertility and other 12 
reproductive system complications, bench science still relies on 2D and animal studies, 13 
which regularly have been criticized due to their inability to mimic the human body. 14 
Particular challenges in 2D studies include the inability to mimic fluid dynamics, gametes 15 
modulation and their crosstalk, hormonal patterns as well as the low quality and viability 16 
of gametes and embryos. Animal models also present other drawbacks, namely the 17 
absence of menstruation, making it difficult to establish a reliable predictive model for 18 
the human system. Additionally, reproductive studies should not be limited to the 19 
fallopian tube as the sole responsible for most infertility cases, but instead the research 20 
spectrum should be widened to the whole reproductive system given the tight 21 
interconnectivity between each and every organ. In the last few decades, new in vitro 22 
technologies have been developed and applied to the study of reproductive system 23 
complications.  These systems allow to create complex three-dimensional structures, 24 
which are therefore able to more closely resemble specific microenvironments and 25 
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provide more realistic physical and biochemical cues. 3D (bio)printing, organoids and 26 
organs-on-chips are some of the dynamic technologies which are replacing conventionally 27 
employed static 2D culture. Herein, we provide an overview of the challenges found in 28 
conventional 2D and animal models of the reproductive system and present potential 29 
technological solutions for those same challenges. 30 
 31 
Keywords: Infertility; Reproductive challenges; Biofabrication; Additive Manufacturing; 32 
Organs-on-chips. 33 
 34 
Introduction  35 
Infertility is defined as the inability to achieve clinical pregnancy after one year of 36 
regular unprotected intercourse and poses as a global public health issue [1]. According 37 
to the World Health Organization (WHO), about one in every four couples have been 38 
affected by infertility in developing countries [2]. This problem has a major impact not 39 
only on public human health, but also on the livestock industry, animal husbandry, and 40 
world food production. In this respect, abnormal ovulation and  tubal obstruction are the 41 
main problems in female infertility, which lead to deficient fertilization as the oocyte is 42 
not able to correctly await fertilization in the fallopian tube [3]. Cancer is also correlated 43 
to infertility due to the gonadotoxic properties of some anticancer treatments [4]. 44 
The female reproductive system is mainly composed by ovaries, fallopian tubes, 45 
oviduct, uterus, and cervix [5]. Each organ is dynamic, responding to fluctuating hormonal 46 
concentrations driven by the pituitary gland and ovaries. This influences the ovulation, 47 
fertilization, embryo implantation, and placentation, making the reproductive system a 48 
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highly complex system to study [6]. The main research and clinical reproductive advances 49 
were achieved so far by means of bi-dimensional (2D) in vitro culture studies, which will 50 
be later discussed.  However, this type of model presents problems related to the lack of 51 
mimicry of the physiological system. Operative conditions such as pH, osmolarity, light 52 
availability as well as availability of specific cues and factors are among the factors that 53 
make 2D in vitro studies inadequate [7]. Inappropriate culture conditions and resulting 54 
inadequate models can be detrimental and be a limitation in this research field. To our 55 
best knowledge, currently, most studies have a limited scope, focusing on studying mainly 56 
the oviduct and neglecting the bigger picture. However, it is indispensable to have a global 57 
perspective, to be able to understand the whole process and comprehend its dynamics. 58 
Gamete/embryo handling and cell culture media can also be a limiting factor. For 59 
instance, the medium typically employed in 2D culture of embryos made by in vitro 60 
fertilization (IVF) procedures can effectively impact birth weight [8]. Despite all the 61 
advances in reproductive biotechnology, current operative conditions do not entirely 62 
mimic interactions and hormonal patterns observed in the natural morpho- physiological 63 
environment [9]. It is clear that in vitro-produced embryos differ markedly from those 64 
that have been developed in vivo, due to embryo manipulation and due to the static 65 
nature of cultures [10]. 66 
Nonetheless, when studying human fertility, animal models are not sufficiently useful 67 
either, since a reliable comparison cannot be made between these two systems. Animal 68 
models continue to face several challenges given that they are not entirely predictive of 69 
the human body function and there still are some safety and efficacy issues related to 70 
them [7].  Additionally, these models are significantly different from the human in vivo 71 
conditions, since most of them do not menstruate nor have the same regulatory patterns 72 
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or specific hormones [11]. Rodents in particular are also insensitive to certain classes of 73 
chemical compounds, compromising the conclusiveness of any toxicological risk 74 
assessment intended to predict effects in humans [11]. 75 
In the present work we review various limitations encountered in reproductive 76 
research, as well as various novel technological solutions which may help advance the 77 
field.   78 
 79 
Conventional 2D cell culture and common hurdles in reproductive research 80 
In vitro static 2D cell culture is the most widely used strategy in the study of the female 81 
tract. It is a low cost, simple and convenient approach which also enables easy 82 
downstream processing [12,13]. A considerable number of related assays and techniques 83 
were also extensively developed turning 2D cell culture into a flexible and quick platform 84 
that can be easily employed in reproductive studies. In conventional 2D culture, cells are 85 
seeded on a plastic surface and allowed to grow in a bidirectional manner, having access 86 
to both media and growth factors [12,13].  The plastic surface can also be further 87 
functionalised with different materials and proteins in order to resemble  certain 88 
microenvironments [14].  89 
However, various studies alerted the scientific community to the sub-optimal 90 
conditions provided by 2D cell cultures. Particularly, 2D cell culture models can 91 
compromise the viability and reliability of experiments by influencing fundamental 92 
cellular features and in this way affect the correct understanding of the whole organ 93 
function [12,13]. During bidimensional growth, cells can suffer membrane receptor loss, 94 
modifications and alterations in several characteristics, such as genetic patterns, 95 
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hormonal responses, cell differentiation and proliferation rates as well as responses to 96 
different stimuli and secretions [15]. Additionally, during manipulation of biological 97 
samples, these can suffer several manipulations, causing excessive stress to oocytes or 98 
embryos (temperature, light, pH and osmolarity) and compromising their potential [8,16].  99 
Furthermore, in vitro 2D cultures showed to not be adequate for mimicking natural 100 
cellular environments given that the employed cellular monolayer suffers a quick 101 
transformation, making it difficult to maintain nutrient concentration and prevent 102 
metabolite accumulation [16,17]. This phenomenon is observable in cuboidal–columnar 103 
oviduct epithelial cells which change their phenotype into flattened cells with a complete 104 
loss of cilia and a reduced secretory ability, when compared to the normal physiology 105 
(figure 1) [16]. Inadequacies may also be found in 2D ovary cultures, which are not able 106 
to promote ovary follicle maturation due to the inexistence of follicular architecture. 107 
Another limitation found in 2D cell cultures is related to the inability to create a sufficient 108 
air-liquid interface, given that high volumes of medium are needed to supply proper 109 
conditions and most current embryo culture systems are static. Therefore, these systems 110 
often lose cell viability, compromising the experimental efficacy [10].  111 
 112 
Figure 1 - Histological characterization of rat oviduct. Source: [78] 
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One of the most compromising aspects of the bidimensionality found in conventional 113 
cell culture is the lack of naturally occurring interactions between cells and organs. The 114 
oviduct is a good example of a non-reproducible system via 2D cell culture. This organ is 115 
characterised by highly complex interactions, being where the fertilization occurs and 116 
where the embryo develops before migrating to the uterus as a morula. It has a specific 117 
microenvironment that activates gametes, helps avoid polysemic fertilization, promotes 118 
embryo nourishment and provides developmental stimuli. Also, the oviduct wall is able 119 
to recognize the arrival of spermatozoa and even alter their proteome, due to these 120 
interactions [7,18-21]. 121 
In vivo hormonal patterns are also impossible to be fully emulated in 2D cell cultures. 122 
The long- and short-range hormonal signals that are established between the gametes or 123 
embryo and the female tract during pregnancy are a good example of such hormonal 124 
patterns. These signals promote a unique dialogue and generate multiple signalling 125 
cascades and a complex interactome, which may influence the maturation and transport 126 
of gametes, coordinating a successful fertilization and assuring embryo viability [20]. 127 
Genetic patterns are another hurdle found in 2D cell culture, given that many critical 128 
interactions that impact cells at a molecular level cannot be mimicked. The oviduct in 129 
particular has a specific role in embryonic genome activation and reprograming. These 130 
crucial interactions are responsible for creating somatic epigenetic methylation, which in 131 
turn modifies the gene expression by silencing or activating their expression through the 132 
epigenetic marks which later influence the blastocyte’s transcriptome [22-24]. Ferraz et 133 
al. performed a comparative study between in vitro and in vivo embryos which showed 134 
that active DNA demethylation was higher in in vivo zygotes [15]. 135 
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Naturally occurring mechanical forces resulting from ECM stiffness and other 136 
mechanical stresses are also factors that cannot be mimicked in 2D in vitro assays. When 137 
sensed, these forces are converted by cells into inner biochemical signals which influence 138 
their development. In particular, embryonic and extra-embryonic fluids have a critical role 139 
in the embryo behaviour since they modulate tensional and frictional stress and 140 
hydrostatic pressure [23]. Shear stress is one of the mechanical stresses that result from 141 
fluid flow, peristaltic tubal compression and kinetic friction between embryo and cilia, and 142 
which influence early development of the embryo [25-27]. This mechanical property is 143 
responsible for inducing cell-cell communication, positively affecting the embryo by 144 
refreshing the surrounding fluid, eliminating metabolites produced by the embryos and 145 
influencing genetic factors. Furthermore, mechanical events, such as pulsating muscle 146 
contractions, cilia beating and sperm motility, act in a positive way by increasing the 147 
dispersion and availability of hormones and nutrients [26]. Shear stress can modulate 148 
several important developmental mechanisms in pre-implanted embryos and should be 149 
recreated in in vitro experiments.  150 
 Overall, 2D models are inefficient in promoting these normal environmental cues 151 
along the tract and the interaction between the different female organs. Such limitations 152 
may affect not only the gametes but also the embryo in their DNA methylation dynamics 153 
or hormonal signalling. As such, all these experimental conditions may impact the 154 
embryo’s outcome and consequently promote sub-optimal conditions in the reproductive 155 
system studies.  156 
 157 
3D cell culture approaches 158 
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 Recent biotechnological advances brought about new techniques and more 159 
complex approaches to investigate the female reproductive system. These allow to more 160 
closely mimic the human body, having the potential to address the limitations previously 161 
mentioned.  Three-dimensional (3D) cell culture, organoid models and organ-on-chip are 162 
some of these new advanced systems, which will be discussed below.    163 
 164 
3D cell culture systems emerged as a way to overcome the hurdles reported above, 165 
given their ability to more closely mimic the macro- and micro-architecture of tissues and 166 
organs, and to stimulate cells with the appropriate biochemical and biomechanical cues. 167 
The transition from 2D to 3D models represents a breakthrough in cell biology and related 168 
areas since it can lead to levels of tissue organisation never seen before. In these cell 169 
culture systems, cells grow and organize themselves in a 3D architecture, promoting a 170 
more complex structures and representing a more in vivo-like biological 171 
microenvironment. In this way, the three-dimensionality improves and promotes 172 
communication between cells, replicating cell and tissue physiology, mimicking 173 
mechanical cues, allowing communication between the cell and its matrix and taking into 174 
account the spatial organization of the tissue [12-14].  Moreover, 3D approach allows cells 175 
to maintain the basal-apical polarity, as well as to retain their genetic and epigenetic 176 
patterns. However, these models may in certain cases still face some challenges involving 177 
deficient non-homogenous distribution of cells, nutrients and oxygen, inefficient removal 178 
of waste, lack of vascularisation and therefore limited reliability and repeatability [28]. 179 
The characteristics as well as pros and cons of several promising 3D-enabling technologies 180 
will be described below. 181 
 182 
9 
 
Spheroids are simple 3D models that take advantage of the capability of adherent 183 
cells to aggregate. These cell aggregates are able to mimic the microenvironment of 184 
various tissues as well as their cell-cell and cell-ECM interactions. However, the 185 
generation of necrotic cores is generally a considerable challenge of this technique, due 186 
to the lack of nutrients, oxygen and waste diffusion to/from the center of the cell 187 
aggregate. Due to its simplicity and mimicry properties, spheroids are widely used in drug 188 
screening assays [28]. Lawrenson et al have successfully developed a fallopian tube 189 
spheroid model composed of primary fallopian tube secretory epithelial cells. The 190 
employed spheroids were able to restore the three-dimensional in vivo architecture 191 
although at a low proliferative rate. In this way, it was possible to show that spheroid 192 
technologies are able to generate relevant models to study the quiescent status of normal 193 
secretory epithelial cells [29]. 194 
 195 
Microcapsules are mainly used as 3D cell carriers, and have been employed in the 196 
delivery of cells for the treatment of conditions such as cancer and diabetes [30-33]. 197 
Microcapsules are small sized systems, ranging from 100 μm to 750 μm, generally made 198 
of natural or synthetic polymers and able to encapsulate hundreds to thousands of cells. 199 
The reduced capsule size allows to increase oxygen, nutrient and waste diffusion and 200 
allow delivery of cells and therapeutics via small incisions or catheters, therefore avoiding 201 
major surgeries [32, 33]. Dorati et al developed a 3D barium-alginate microcapsule for 202 
enriching the medium employed in in vitro embryo production from cryopreserved 203 
domestic cat vitrified oocytes. The results of this study showed that while using vitrified 204 
oocytes 3D culture per se did not capacitate the viability of vitrified cat oocytes. However, 205 
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when using a culture condition enriched with 3D alginate microcapsules, it was possible 206 
to promote maturation and embryo development [34]. 207 
 208 
Organoid models are composed of 3D aggregates of cells, formed either from 209 
pluripotent stem cells or multipotent organ-specific adult stem cells [35].  These 3D 210 
models have a higher degree of complexity, and, therefore, are able to more reliably 211 
mimic tissue’s histology, functionality and physiology, when comparing to the classical 2D 212 
in vitro cell culture. Additionally, organoids are able to retain tissue phenotypical and 213 
functional properties [36].  In a study by Kessler and co-workers it was possible to 214 
successfully produce a fallopian tube organoid made from stem cells derived from the 215 
human fallopian tube epithelium [37].  This model could mimic the normal physiology and 216 
anatomy of the human fallopian tube epithelium, maintain the phenotypic patterns for 217 
several months and differentiate epithelial cells into secretory and ciliated cells. Finally, 218 
the authors were able to observe a high degree of similarity between the organoid and 219 
its human counterpart. Also using an organoid model, Buretto et al created an 220 
endometrium model that could efficiently reproduce the tissue physiology and allow 221 
long-term expansion [36].  Despite all, organoid morphology and architecture are still a 222 
limitation of this type of 3D cell culture technique. For example, in oviduct organoids, 223 
gametes and embryos can only gain access by means of a micro-puncture to the organoid, 224 
which can be invasive and damaging to the model. Additionally, this procedure is 225 
performed manually, therefore increasing the susceptibility to error [16]. 226 
 227 
Scaffolds are support constructs that foster cell and tissue growth. They can also 228 
further influence cell and tissue development by providing topographical cues and/or 229 
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various biochemical cues, such as growth factors and drugs [38]. Scaffolds can be created 230 
using different physical and/or chemical approaches and composed of a wide range of 231 
materials, either natural, synthetic or hybrid. Some of the most promising scaffolds are 232 
composed of hydrogels and manufactured by means of biofabrication techniques [39-41].  233 
 234 
Hydrogels are three-dimensional networks composed of physically or chemically 235 
crosslinked hydrophilic polymers. These are biocompatible and, although being water 236 
insoluble, can uptake high amounts of water or other liquids and may have their physical 237 
conformation tuned in terms of mechanical and morphological properties [42,43]. The 238 
utilization of hydrogels may however be limited given that some of them are created 239 
employing harmful crosslinkers and most lack adequate mechanical and degradability 240 
properties. These limitations are usually overcome by combining both natural and 241 
synthetic polymers in order to obtain hydrogels with tailored properties [42-44].  Joo et 242 
al used a collagen-based hydrogel for seeding oocytes and investigate the hormone 243 
patterns and oocyte maturation. The employed hydrogel was shown to indeed contribute 244 
to the maintenance of follicle native function and its phenotypic patterns when cultured 245 
in vitro [45].  246 
 247 
Advanced scaffolds are constructs typically manufactured by means of technologies 248 
such as electrospinning, among others [46] . Due to the precision of these technologies, 249 
scaffolds can be manufactured with tailored morphology and mechanical properties, 250 
maximizing the biomimetic properties of these systems [39,47]. Furthermore, by 251 
employing these technologies it is possible to achieve greater levels of repeatability and 252 
reproducibility, when compared to other cell culture approaches [48]. However, similarly 253 
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to other scaffolds, limited nutrient, oxygen and waste diffusion in large scaffold volumes, 254 
heterogeneous cell distribution and architectural challenges are among the drawbacks 255 
that may eventually be observed in these systems [48,49]. In a study by Liverani et al 256 
employing electrospun fibrous scaffolds for culture of porcine follicles, it was possible to 257 
observe that scaffold morphology and composition had crucial roles in enabling the ovary 258 
to maintain its normal function and follicle morphology, given that the scaffold could 259 
closely mimic the in vivo tissue [50]. 260 
Table 1 - Advantages and disadvantages of the different 3D cell culture techniques 261 
3D MODELS ADVANTAGES DISADVANTAGES REFERENCES 
SPHEROIDS 
 
-Simple  
-Mimics in vivo interactions  
-Necrotic cores 
-Size variability  
- Long-term culture 
difficulty  
-Simplified architecture 
[29,51-54] 
ORGANOIDS -Emulate interaction 
between cells of different 
tissues  
-Higher degree of 
complexity 
-Can be patient specific 
-Necrotic cores 
-Size variability 
-Need validation  
 
[54-56] 
HYDROGEL SCAFFOLDS -Emulate in vivo ECM 
interaction 
- Physical or chemical 
crosslinking 
- Highy reproducible  
-Inefficient exchange of 
substances 
-Simplified architecture 
-Difficult cell recovery 
[43,54] 
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 262 
Advanced technological solutions 263 
Nowadays there are new advanced technologies that are capable of further 264 
replicating the complex heterogeneity found in the reproductive system in a more precise 265 
manner and therefore being able to closely resemble in vivo microenvironments. These 266 
technologies include 3D printing and bioprinting, as well as microfluidic systems and 267 
organ-on-chips, which will be discussed below. 268 
 269 
3D printed scaffolds and devices. 3D printing technology is based on the 270 
fabrication of 3D structures by consecutive deposition of layers of material. It was first 271 
used in 1986 by Charles W. Hu, who first developed stereolithography [59].  By using 272 
computer-aided design (CAD) software and medical imaging, simple or complex physical 273 
shapes can be obtained with an unprecedented speed and detail. The development and 274 
optimisation of new materials, combined with reduced manufacturing costs and 275 
advanced printers, enabled the use of 3D printing in research labs and industrial settings 276 
[60-62]. This technology can be adopted for a broad range of applications, from aviation 277 
and car industries to healthcare. In the medical field, the use of biocompatible materials, 278 
such as polylactic acid (PLA) and acrylonitrile butadiene styrene (ABS) allowed to produce 279 
scaffolds that could be used in certain medical scenarios [60-62]. Additionally, 3D printing 280 
presents a tremendous potential for scaffold production due to the increased reliability 281 
BIOFABRICATED 
SCAFFOLDS 
-Mimics the in vivo 
microenvironment 
- High porosity  
-Tailored morphology and 
mechanical properties  
-Heterogeneous cell 
distribution  
- Limited diffusion  
[54,57,58] 
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and reproducibility, when compared to other methods. Post-manufacturing treatments, 282 
such as heat treatments and hot isostatic pressing, are used to tailor the properties of 283 
scaffolds, by modifying their microstructure or surface roughness [62]. 284 
3D Bioprinting (a very specific type of 3D printing) also applies a layer-by-layer 285 
concept however, unlike standard 3D printing, it relies instead on the deposition of cell-286 
laden filaments or cell-containing droplets into specific substrates in order to generate 287 
three-dimensional biological structures [59].  288 
Regarding the application of 3D printing in the study of the reproductive system, 289 
the best example can be found in a study by Laronda et al. describing the development of 290 
a bioprosthetic ovary. In this case, a 3D printed microporous scaffold was able to provide 291 
space and nutrition diffusion for follicle survival and maturation and enabled the growth 292 
of an ovary-like vascularization, which is fundamental for the circulation of hormones 293 
around the follicle. This system also enabled the development of a corpus luteus to 294 
produce hormones, after the ovulation, and egg release without mechanical manipulation 295 
or digestion [63].  296 
 297 
 Microfluidic systems are another strategy available to study the reproductive 298 
field in a more complex manner. Microfluidic systems are small devices with a single or a 299 
set of sub-millimetric channels. These micro-channels allow the injection of liquids or 300 
gases through inlets connected to tubing and/or syringe/pump adapters. Such devices can 301 
be used for several purposes not only in the biomedical field but also in chemistry and 302 
other areas. The utilization of microfluidics for reproductive purposes has increased in the 303 
past years due to their ability to mimic the reproductive system in a more efficient and 304 
physiological way [19]. Microfluidics has already been used on sperm motility tests 305 
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allowing to study sperm rheotaxis and chemotaxis [64,65], gamete and embryo culture 306 
and evaluation [23, 66], transportation of embryos and respective monitoring [66,67] and 307 
to remove cumulus cells and zona pellucida [17, 68]. For example, Angione et al were able 308 
to develop a microfluidic device that not only allowed perfusion and live imaging of the 309 
living system but also a precise and flexible handling of individual oocytes and embryos 310 
[69].  Another example is the device developed by Yin et al. which could mimic an in vivo-311 
like 3D placenta in a chip [70]. In this study, the construct was designed with two parallel 312 
cell channels separated by a middle matrix channel, and with a perfusion flow that could 313 
generate a near-physiological dynamic microenvironment. In this way, it was possible to 314 
successfully build a device that allowed to study placental responses to toxicological 315 
environments. 316 
 317 
Organs-on-chips are complex microfluidic devices, designed for emulating the 318 
architecture, function and dynamic environment of organs (or portions thereof). Organs-319 
on-chips may consist of very simple devices or highly complex device systems, often 320 
integrating components such as valves or pumps into the design itself. These systems can 321 
for instance allow fluid mixing, as well as generate fluid gradients and microdroplets [71]. 322 
Furthermore, the integration of flow perfusion and the ability to co-culture cells in a 323 
controlled manner makes these devices more able to resemble in vivo conditions.  324 
Organs-on-chips are highly suitable for laboratory assays since they are small, 325 
employ low volumes of reagents being therefore less expensive to operate, and are able 326 
to generate and maintain a stable microenvironment with precise control over spatial and 327 
temporal dynamics. Additionally, these systems enable  a greater capability for batch 328 
sample processing and greater screening scope  [19, 72]. These systems are already being 329 
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used for medical and pharmaceutical purposes, namely in drug screening and 330 
pharmacokinetic and pharmacodynamic tests [5]. These devices are also able to better 331 
simulate natural environments which are useful for embryo culture optimization. Organs-332 
on-chips can also mimic naturally occurring physical and mechanical stimuli, enabling cells 333 
to experience relevant physiological cues that directly affect their biological function [73]. 334 
Additionally, medium perfusion allows to  improve nutrient supply, clearance of waste 335 
products and metabolic profiling [73]. Furthermore, organs-on-chips are adequate for 336 
profiling the cell secretome in culture medium and, therefore, used for searching specific 337 
biomarkers [74]. In the future, this technology may be used as a fertilization platform, 338 
improving the in vitro fertilization rate and quality, as well as simultaneously integrate a 339 
variety of functional tests that supplement the information about embryos or gametes. 340 
Finally, by providing an environment with controlled osmolality, temperature, and pH, 341 
organ-on-chip devices could eventually reduce the stress typically imposed on embryos 342 
and  enable spermatozoa and oocyte interaction to take place in in vivo-like 343 
environments, generating  embryos more suitable for implantation [19]. The most 344 
advanced examples of organ-on-chip devices directed at reproductive studies were 345 
developed by Ferraz et al. [21] and Xiao et al. [6]. 346 
In the first case, a polydimethylsiloxane (PDMS) microfluidic oviduct-on-chip device 347 
was developed, comprising two independent and perfusable 370 μm deep compartments 348 
separated by a porous membrane. To mimic the oviduct, a confluent oviduct epithelial 349 
cell layer was grown on the top of the membrane. The compartments were designed to 350 
ensure shear stress and to entrap the oocytes in an apical compartment. This device was 351 
built with a thin design so that the apical compartment of the device would allow live 352 
imaging of the epithelial cells, gametes, and embryos inside the chip [21]. This 3D model 353 
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allowed a deeper understanding in the early maternal-gamete/embryo interaction with 354 
production of zygotes highly resembling in vivo zygotes, within a microenvironment 355 
closely resembling in vivo conditions.  356 
In the latter case, a complex multi-organ on chip (called EVATAR) was composed of 357 
five different tissues (cervix, fallopian tube, ovaries, uterus, and liver) connected by a 358 
complex microfluidic device circulating flow between all tissues. Given that the use of 359 
microfluidic devices enable the control of flow rates and real-time monitoring of 360 
metabolites, drug compounds, signalling molecules and hormones [5,65], this device 361 
could more realistically mimic the complexity of the reproductive female system, when 362 
comparing to 2D petri dishes or animal models. Additionally, this organ-on-chip was able 363 
to mimic the 28-day in vivo human follicular and luteal phase hormone synthesis and 364 
hence enable the provision of steroid and peptide hormones [6]. Such systems represent 365 
the next step in the study of the female reproductive system and may become an 366 
important tool for personalized medicine purposes in the future. Furthermore, with the 367 
rise of induced pluripotent stem cells (iPSC) such systems could also become patient-368 
specific and therefore emulate even more closely the dynamic human tissue interactions 369 
[75,76]. 370 
 371 
In general, such complex microfluidic platforms can help reveal more biological 372 
insights more reliably than usual lab assays, since they can recreate the physiological 373 
microenvironment, replicating many features such as chemical gradients, fluid dynamics, 374 
surface interactions and morphologies [75].  However, before widespread adoption, it is 375 
important to make sure that these devices are fully tested and characterized in order to 376 
safeguard the reliability of results obtained. As an example, the material most commonly 377 
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used in the manufacture of microfluidic and organ-on-chip devices – PDMS – undesirably 378 
binds to some classes of molecules and some additive manufacturing materials may be 379 
toxic to cells [76].  380 
 381 
Conclusions and future perspectives 382 
Conventional 2D static culture methods are clearly uncapable of fully mimicking 383 
the natural environment where mammalian embryos typically develop under constant 384 
exposure to complex combinations of stimuli, crosstalk and cascade reactions.  Advanced 385 
technologies such as organoids, bioprinting and organs-on-chips show the potential to 386 
address these limitations by ultimately enabling the creation of 3D devices and constructs 387 
where embryos and micro replicas of various reproductive organs and tissues may be 388 
grown in close communication with each other. The ability to spatially control the three-389 
dimensional positioning of all these elements as well as the ability to accurately control 390 
their ability to communicate amongst themselves provides a powerful means to perform 391 
systematic in-depth studies where the role of each of these elements can be elucidated 392 
and quantified as the embryo development progresses. Apart from simply mimicking 393 
normal physiological conditions, it may also become possible to induce abnormal stimuli 394 
and conditions, therefore enabling the study and understanding of diseased or abnormal 395 
states which, apart from rarely occurring in nature, may also be extremely difficult or even 396 
impossible to properly study in conventional in vivo and in vitro conditions. 397 
Despite the unquestionable potential of these new technologies, it is however 398 
important to keep in mind that they are fairly recent and are still rarely employed in 399 
reproductive studies. In that sense, there is still a long and arduous way to go until such 400 
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technologies become routinely employed for reproductive purposes. Not only the 401 
technology needs to be further developed in order to achieve its full potential, but it also 402 
needs to become standardized so that results obtained from different studies can be 403 
adequately combined and compared. Furthermore, and given the dynamic complexity of 404 
the biological systems generated in this way, it will be equally important to assure the 405 
quality and speed of acquisition of all sensorial and analytical methods employed. 406 
Overall, the new technologies herein described show the potential to 407 
revolutionize reproductive research as well as human and animal reproduction as a 408 
whole, although much work still needs to be done so that these technologies may become 409 
standardized and routinely adopted in the field. 410 
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